Showing 3491-3500 of 4062 results for "".
- Market Scope: Factors Driving Retinal Pharma Pipelines are Injection Interval, Safety, and Pricehttps://modernod.com/news/market-scope-factors-driving-retinal-pharma-pipelines-are-injection-interval-safety-and-price/2480338/Longer injection intervals without gene therapy might be the theme for retinal pharmaceuticals in 2021, thanks to subsidiaries of the Roche Group filing marketing ap
- SyncThink Receives Second FDA Clearance for Mobile, Rapid Test for Concussionhttps://modernod.com/news/syncthink-receives-second-fda-clearance-for-first-mobile-rapid-test-for-concussion/2480327/SyncThink has received FDA clearance for its EYE-SYNC technology as an aid to concussion, or mild traumatic brain injury (mTBI) diagnosis. EYE-SYNC received breakthrough device designation from the FDA in 2019, following the initial clearance and commercialization of the technology plat
- Ludwin Monz Stepping Down as CEO of Carl Zeiss Meditechttps://modernod.com/news/ludwin-monz-stepping-down-as-ceo-of-carl-zeiss-meditec/2480316/President and CEO of Carl Zeiss Meditec AG Ludwin Monz, PhD, announced that he will not be accepting another term in office, and will be stepping down from his postion effective December 31, 2021. The supervisory board has appointed Markus Weber, PhD, as the new President and
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Aerie Pharmaceuticals Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEOhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-interim-executive-chair-and-departure-of-chairman-and-ceo/2480293/Aerie Pharmaceuticals announced that it is executing its succession plan and that effective September 17, 2021, Vicente Anido, PhD, no longer serves as the company’s Chairman and Chief Executive Officer or as a director of the company. Consistent with the succession plan in p
- TissueTech Hosts Inaugural Leadership Summit to Discuss Best Practices on Regenerative Medicinehttps://modernod.com/news/tissuetech-hosts-inaugural-leadership-summit-to-discuss-best-practices-on-regenerative-medicine/2480288/TissueTech announced that the company had completed its first physician leadership summit, Beyond the Horizon 2021,
- Voptica Introduces Inverted Meniscus IOL to Improve Peripheral Vision at ESCRShttps://modernod.com/news/voptica-introduces-inverted-meniscus-iol-to-improve-peripheral-vision-at-escrs/2480285/Voptica SL has introduced what it is calling the first and only inverted meniscus intraocular lens (ArtIOLs) to improve peripheral vision, according to a company news release. Introduced at the 2021 ESCRS symposium in Amsterdam, ArtIOLs mimic the optics of the natural cry
- Luneau Technology and Optovue Announce Mergerhttps://modernod.com/news/luneau-technology-and-optovue-announce-merger/2480284/France-based Luneau Technology Group, a provider of wavefront-based diagnostic and finishing solutions, announced it is merging with Optovue. Terms of the deal were not disclosed. Founded by Jay Wei in 2003, Optovue develops high-speed OCT and OCT-A technology
- Glaukos Announces Settlement of Patent Litigation with Ivantishttps://modernod.com/news/glaukos-announces-settlement-of-patent-litigation-with-ivantis/2480278/Glaukos announced it has entered into a settlement agreement with Ivantis agreeing to terminate the patent infringement lawsuit Glaukos initiated on April 14, 2018 in the U.S. District Court for the Central District of California, Southern Division, concerning Ivantis’ Hydrus Micr
- Neurolens Names Pierre Bertrand Chief Executive Officerhttps://modernod.com/news/neurolens-names-pierre-bertrand-chief-executive-officer/2480277/Neurolens has named Pierre Bertrand Chief Executive Officer. A senior executive with experience in the eye care space, Mr. Bertrand brings more than 20 years of marketing and strategic expertise to Neurolens. In his role as Chief Executive Officer, Mr. Bertrand will be respons